Aug 3, 2026 08:01AM
Aug 3, 2026 08:00AM
Jul 29, 2026 06:53AM
Jul 28, 2026 07:00AM
Jul 28, 2026 07:00AM
May 28, 2026 11:00AM
May 28, 2026 11:00AM Pemvidutide Demonstrates Significant Metabolic Improvements in Patients with MASH in New 48‑Week IMPACT Phase 2b Data Presented at EASL 2026
May 27, 2026 08:01AM
May 27, 2026 08:00AM
May 19, 2026 06:48AM
May 13, 2026 08:30AM
May 13, 2026 07:30AM
May 13, 2026 07:15AM
Mar 27, 2026 10:53AM Jefferies Reiterates Buy Rating on Altimmune (ALT) as company enters 'execution stage'
Mar 17, 2026 06:46AM
Mar 5, 2026 11:31AM
Mar 5, 2026 07:00AM
Jan 29, 2026 05:54PM
Jan 29, 2026 05:54PM
Jan 27, 2026 09:25PM
Jan 27, 2026 09:25PM Altimmune Announces Pricing of $75 Million Registered Direct Offering of Common Stock
Jan 27, 2026 06:32AM
Jan 5, 2026 07:31AM
Jan 5, 2026 07:30AM
Dec 19, 2025 06:30AM
Dec 19, 2025 06:30AM
Dec 1, 2025 07:31AM
Dec 1, 2025 07:30AM Altimmune Announces CEO Transition and Succession Plan
Nov 12, 2025 04:47AM
Nov 11, 2025 08:52AM
Nov 11, 2025 08:51AM
Nov 7, 2025 08:06AM
Nov 7, 2025 08:05AM
Nov 6, 2025 07:00AM
Nov 3, 2025 07:30AM Altimmune completes enrollment in alcohol use disorder trial
Nov 3, 2025 07:30AM
Oct 20, 2025 07:30AM
Sep 29, 2025 07:30AM
Sep 29, 2025 07:30AM
Aug 19, 2025 07:30AM
Aug 19, 2025 07:30AM
Aug 12, 2025 07:00AM Altimmune Announces Second Quarter 2025 Financial Results and Business Update
Aug 11, 2025 07:30AM
Aug 11, 2025 07:30AM
Jul 9, 2025 07:30AM
Jul 9, 2025 07:30AM
Jun 26, 2025 07:02AM
Jun 26, 2025 07:00AM
Jun 25, 2025 07:12PM Altimmune to Announce Topline 24 Week Results from its IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH on Thursday, June 26
Jun 13, 2025 07:30AM

328,148 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All